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INTEREST in the serum mucoprotein content in cancer dates from the observa-
tions of Brdicka (1933, 1937), who discovered the presence in the protein-free
filtrate from malignant serum of some substance giving a characteristic polaro-
graphic wave. Later work, particularly by Winzler and Burk (1943), indicated
that this substance was probably a mucoprotein and methods for its estimation in
serum were developed (Winzler and Smyth, 1948; Petermann and Hogness, 1948).
It was soon evident that the concentration of serum mucoprotein was frequently
above normalinpatientssufferingfrom cancer andalsoinratsbearingexperimental
tumours (Shetlar, Erwin and Everett, 1950). This increase was not specific
however for malignant diseases as similar results were recorded in rheumatism,
tuberculosis, and in other infections (Seibert, Seibert, Atno and Campbell, 1947;
Shetlar, Shetlar, Richmond and Everett, 1950; Greenspan, 1954).
In the meantime interest in urinary mucoproteins was aroused by the work of
Tamm and Horsfall (1950, 1952), who isolated from normal urine a mucoprotein
fraction which was an active inhibitor ofinfluenza virus haemagglutination. This
work suggested to us that an investigation of urinary mucoproteins in cancer
would be of interest, and a method for the characterisation and estimation of a
urine mucoprotein fraction which could be applied conveniently to a series of
cases was devised (Anderson and Maclagan, 1955a). At the same time some
modifications were introduced into existing methods ofserum mucoprotein estima-
tion (Anderson and Maclagan, 1955b).
The present paper deals with the application of these methods to normal
subjects and to a series ofpatients suffering from cancer and from other diseases.
A preliminary report has appeared elsewhere (British Empire Cancer Campaign,
Report, 1954; Anderson, Lockey and Maclagan, 1955a).
MATERIAL AND METHODS
Details of the 399 subjects investigated are given in Table I. They have been
divided into three main groups consisting of normal, non-malignant and cancer
cases. In all cases the diagnosis was well established on clinical and radiological
or pathological grounds, histological confirmation being available in 101 ofthe 114
cases of cancer.
Urine mucoprotein estimation
The urine estimations were performed on 24-hour specimens. The method of
Anderson and Maclagan (1955a) was used without modification except that in210 EUNICE LOCKEY, A. J. ANDERSON AND N. F. MACLAGAN
TABLE I.-Analysis of Subjects Investigated.
Number
of cases.
63
7
70
59
26
9
5
6
9
5
3
7
17
69
215
Serum
tests.
71
29
100
61
32
Urine
tests.
42
27
69
11
13
15
5
6
0
3
0
9
5
4
10
17
9
5
4
10
16
111
275
42
44
25
20
20
8
37
196
24
25
18
12
20
8
36
143
Clinical diagnosis.
A. Nornal group:
1. Men and non-pregnant women
2. Pregnant women
Totals
B. N.on-malignant group:
1. Collagen diseases-
(a) Rheumatoid arthritis
(b) Ankylosing spondylitis
2 Liver diseases-
(a) Infective hepatitis
(b) Cirrhosis .
(c) Obstructive jaundice .
3. Endocrine diseases-
(a) Thyroid dysfunction
(b) Diabetes mellitus
(c) Others . . . .
4. Infective diseases-
(a) Glandular fever
(b) Bacterial infections
5. Miscellaneous-
Osteoarthritis; renalcalculi; coronaryocclusion;
hypertension; sarcoidosis; prostatic hyper-
trophy; blood dyscrasias; ulcerative colitis;
fractures; C.N.S. lesions; peptic ulcers, etc.
Totals
c. Malignant group:
1. Lymphomata (Hodgkin's disease; leukaemia;
lymphosarcoma) . . . . . . 22
2. Alimentary tract-
Oesophagus, stomach, colon, and rectum . . 22
3. Bronchus . . . . . . . . 20
4. Breast . . . . . . . 16
a. Bone (myeloma, 7, osteogenic sarcoma 3) . . 10
6. Bladder . . . . . . . 8
7. Others . . . . . . . 16
Totals . . . . . . . . . 114
patients with a high urine mucoprotein concentration a smaller initial sample was
used. In such cases 20 ml., or less, ofurine were taken and diluted to 40 ml. with
water before the addition of sulphosalicylic acid. It should be noted that in this
method the presence of albuminuria has the effect of decreasing the recovery of
added mucoprotein so that in such cases the value obtained is probably too low.
In the present series about 20 per cent of patients had albuminuria which was
usually slight. The possible effect of this factor is discussed further below.
Serum mucoprotein estimation
The following method is based on that of Winzler, Devor, Mehl and Smyth
(1948) and Ayala, Moore and Hess (1951) and has been described briefly elsewhere
(Anderson andMaclagan, 1955b). The conditions ofprecipitation must befollowed
exactly to obtain reproducible results. The degree of reproducibility with a.MUCOPROTEINS IN CANCER
single worker is about ± 5 per cent, but larger variations have been found between
different workers, as has been noted by Mandel, Gorsuch and Cooper (1955).
These variations are presumably due to different degrees of co-precipitation of
mucoproteins with other serum proteins.
Reagents:
Aqueous saturated sodium chloride solution. 0 9 per cent (w/v) aqueous
sodium chloride.
0-2M sulphosalicylic acid. This reagent must be prepared fresh each day.
5 per cent (w/v) phosphotungstic acid in 2N HCI. This reagent is stable
for at least 14 days at room temperature.
Diphenylamine reagent. Diphenylamine (1 g.) dissolved in a mixture
of 90 ml. of glacial acetic acid and 10 ml. of conc. H2SO4. This reagent is
stable for at least 7 days at room temperature.
Sulphosalicylic acid, reagent grade. All other reagents AnalaR.
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FIG. 1.-Serum mucoprotein estimation. Calibration curve.
Method.-1 ml. ofserum was pipetted into a 15 ml. tapered centrifuge tube and
1 ml. of0 9percent (w/v)salineadded. Aftermixingthecontentswithaglassstirrer
6 ml. of 0-2M sulphosalicylic acidwere addedimmediately from a pipette, allowing
20 seconds for the delivery with constant stirring. The contents of the tube were
then thoroughly mixed by two inversions. After standing for 30 minutes with
occasional stirring the mixture was filtered through No. 50 Whatman filter paper.
If the filtrate was cloudy it was refiltered. A cloudy filtrate usually indicated a
high mucoprotein concentration. Three ml. of the filtrate were then pipetted into
another 15 ml. tapered centrifuge tube and 2 ml. of 5 per cent (w/v) phospho-
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tungstic acid in 2N HCl added. The contents were stirred immediately and after
the precipitate had flocculated (about 10 minutes) it was centrifuged down. The
precipitate was then washed once with 8 ml. of acetone and re-centrifuged. The
supernatant fluid was decanted and the tubes drained by inversion for about 30
seconds onfilter paper. (Draining forlongerperiods causes an appreciable decrease
in the solubility of the mucoprotein.)
The precipitate was then treated with 2 ml. of water previously adjusted to
about pH 9 with 0. 1N NaOH. The mixture was stirred occasionally for 10 minutes
and 8 ml. of acetone added. After thorough stirring the mucoprotein was precipi-
tated by addition of one drop of saturated aqueous sodium chloride solution.
After further stirring the mucoprotein was allowed to flocculate (from 5 to 60
minutes) and then centrifuged. The supernatant fluid was rejected and the tubes
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FIG. 2.-Relationship between urine mucoprotein and specific gravity in cancer.
Correlation coefficient = + 0*48.
allowed to drain as above for about 30 seconds. Four ml. of water at pH 9 were
then added, the contents stirred and allowed to stand with occasional stirring for
at least 30 minutes to ensure complete solution of the mucoprotein. The slight
insoluble residue was removed by centrifugation and the supernatant fluid
decanted into a test tube of convenient size. Three ml. were transferred into the
special reaction tube (as used in the method for urine mucoprotein estimation),
followed by 3 ml. of the diphenylamine reagent. After mixing, the contents were
heated at 100° C. for exactly 30 minutes in a boiling water-bath. After cooling
under tap water the colour was then read in a photoelectric absorptiometer using
an Ilford 604 filter (maximum transmission 540 m,.). A blank, consisting of 1 ml.
of0*9 per cent saline in place of 1 ml. ofserum, was set up for each determination.
The results were read from a standard curve obtained from an aqueous solution
of the urine mucoprotein fraction A2 (Anderson and Maclagan, 1955a) employing
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a concentration range offrom 50 to 900 mg. per 100 ml. and expressed as mg. per
100 ml. of serum.
RESULTS
Preliminary observations on urine mucoprotein estimations showed that there
was a definite correlation between the concentration of urinary mucoprotein and
the specific gravity of the 24-hour specimen for all three groups. This correlation
in the cancer group is illustrated in Fig. 2. Statistical analysis showed it to be
highly significant (r + 0-48, P = less than 0.001).
This relationship suggested the use ofa factor obtained by dividing the urinary
mucoprotein concentration, expressed in mg. per 100 ml., by the last two figures
(1000 x excess above unity) of the specific gravity ofthe 24-hour specimen. This
ratio which we have called the " relative urine concentration " (R.U.C.) gives a
measure ofthe mucoprotein excretion relative to the total solids ofthe urine.
TABLE II.-Urine and Serum Mucoprotein Values in Normal Subjects
Mean ± Standard error.
Pregnant
Urine values Male (15). Female (14). female (7).
Relative urine concentration (R.U.C.) . 0*627±0 029 0*566±0 039 0*72±0 024
24-hour volume . . . 1750±88 1070±74 1865±125
Specific gravity . . 1*014340-00714 1*0198±0 0146 1*0129±0*0063
Totalsolids . . . 66-7±3-1 51-9±1 9 63*0±3*7
Mucoprotein mg./24 hours . . . 156±6-71 111±6 15 166±1 11
Mucoprotein mg./100 ml. . . . 93±0-377 10 6±0 58 9-26±1-04
Pregnant
Male (28). Female (26). female (7).
Serum mucoprotein mg./100ml. . . 138v5±5i62 134 3±5i58 154±16-1
Table II shows the values obtained in anormal group ofhealthy adults between
the ages of 17 and 35 years. It will be seen that while there is no significant
difference between the sexes for the serum mucoprotein values, the male subjects
excreted significantly more urine mucoprotein than the females as previously
reported (Anderson and Maclagan, 1955a). It will also be noted that the males
excreted larger amounts oftotal solids than the females presumably on account of
their greater body size. If, therefore, the mucoprotein excretion is compared with
the total solids, as given by the relative urine concentration, we obtain a factor
which is independent of sex and presumably of body size. It has the further
advantage of obviating errors due to incorrect collection of 24-hour specimens.
This factor was therefore selected as most suitable for comparison of the various
clinical groups, which of course included both sexes.
Fig. 3 compares the serum and urine values in malignant disease and it can be
seen that a marked positive correlation was present. Statistical analysis showed
this to be highly significant (r + 0-69, P = less than 0.001). A similar though less
marked correlation is displayed by the 215 non-malignant cases. This appears to
indicate that the mucoproteins that we have estimated in the urine may be at
least partly derived from those estimated in the serum.
Table III gives a general summary of the serum and urine mucoprotein values
in the cases investigated. It will be seen that the highest average figures occur in
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TABLE III.-Statistical Summary of Results
Condition.
Normal (male and female)
Pregnancy.
Endocrine
Renal calculi
Liver
Infections
Ankylosing spondylitis
Rheumatoid arthritis
Cancer
Mean ± Standard error.
C-A
Serum mucoprotein Urine mucoprotein Relative urine
in mg. per 100 ml. per 24 hours. concentration.
136-5±23-93 134i5i 6-06 0 598±0 024
154 ±16d1 166 + 1-11 0-72 +0-024
144 ±10-86 197 ±19-29 0-81 ±0 05
153 ±18-4 154 ±35-1 0*82 ±0 133
173 ±11-6 * *
271 ±18-4 217 ±21-79 1-23 ±0O156
258 ±14-2 153 ±19-9 1.10 ±0O172
256 ±10-7 204 ±25-02 1-06 ±0-08
308 ±15*4 238 ±17-26 1-58 ±0 121
* Urine estimations not performed. The presence of bile in urine
interferes with the colorimetric estimation.
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FIG. 3.-Relationship of serum and urine mucoproteins in malignant disease. + = heat
coagulable protein present in urine; 0 = no heat coagulable protein present in urine.
Correlation coefficient = + 0 69.
malignant disease, but that collagen and infective diseases also show considerable
elevation. Inadditionthere was someelevationofurinary mucoproteinexcretionin
pregnancy and in the endocrine group, and a significant rise of serum mucoprotein
in the liver group. The results in cases of renal calculi were within normal limits.
Fig. 4 and 5 show the detailed results ofthe urine and serum mucoproteins for
various groups of diseases. It will be seen from these figures that although many
high values occurred in the infective and collagen group, the range of values was
greater and high values much more frequent in cancer. Thus in the case of serum,
only 3 non-malignant cases had values greater than 450 mg. per 100 ml. (wide-
spread abdominal sepsis; severe ulcerative colitis; disseminated lupus erythema-
tosus). With the relative urine concentration, values of more than 2-5 were seen
in 5 non-malignant cases (long-standing urinary infection in a paraplegic, severe
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ulcerative colitis, disseminated lupus erythematosus, polyarteritis nodosa and
glandular fever). In the cancer group, on the other hand, the corresponding
figures, drawn from a slightly smaller sample, were 21 for the serum and 12 for
the urine values. The results in the non-malignant cases will not be discussed
further in this paper.
Fig. 6 and 7 give a further analysis of the cancer group, from which it will be
seen that the highest values, both for urine and for serum mucoprotein, occurred
in cases with a wide dissemination of tumour tissue. These included cases with
widespread metastases fromprimarytumours ofvariousorgans, andalsoconditions
such as the leukaemias, Hodgkin's disease and lymphosarcoma, where dissemina-
tion is present from the start ofthe condition. Nevertheless, serum values greater
than 450 mg. per 100 ml. were recorded in 2 cases of apparently localised cancers
and in one where only the local drainage glands appeared involved. This latter was
a case of carcinoma of the bronchus with gross secondary infection ofthe lung and
also showed a very high urinary value. The two localised cases were both cancers
of the oesophagus. Possibly the marked dehydration present in both was partly
responsible for the raised values. The urine was not examined in either of these.
A further point of interest was that many of the cases with low mucoprotein
values and wide dissemination were those involving bone (plasmacytoma and
metastases in bone.)
TABLE IV.-Mucoprotein Values and Type of Cancer Dissemination
Mean ± Standard error.
Number of cases. A
Serum Urine Relative
Serum Urine mucoprotein mucoprotein urine
Group. tests. tests. mg./100 ml. mg./24 hours. concentration.
1. All cancers . . . . 112 85 . 308±15-4 238±17-26 1-58±0-121
2. Lymphoma group . 22 14 . 403±27-3 341±53-4 2-08±0-28
(Hodgkin's disease; leukae-
mia; lymphosarcoma)
3. " Bone " group . . . 15 15 . 216±17-1 189±22-5 1-04±0-102
(multiple myeloma; osteo-
genic sarcoma; secondaries
confined to bone)
4. All cancer not included in 2 or 3 75 56 . 299±19-8 217±20-15 1-55±0-154
Further information as to the influence of tumour site is given in Table IV
from which it can be seen that the mean mucoprotein values of the lymphoma
group were significantly higher, and those ofthe " bone " group were significantly
lower than the general cancer mean. Apart from this relationship there was no
obvious correlation between the results and the tumour site, cases of breast,
bronchus and alimentary tract cancer showing similar distributions of elevated
values.
Attempts to demonstrate a correlation between histological tumour type or the
degree of histological differentiation with mucoprotein levels were unsuccessful.
Fig. 8 shows the effect of surgical treatment of malignant and non-malignant
conditions (17 and 10 cases respectively) on the serum mucoprotein level. It
will be seen that the main tendency is a marked rise during the first few days
following operation, with a return towards normal levels after 2-3 weeks. The
only exceptions were 3 cases of cancer in which either no change (1 case) or a fall
(2 cases) was seen post-operatively. It appears therefore that during the period
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studied any possible fall in serum mucoprotein due to removal of tumour tissue is
usually overshadowed by a general rise which is presumably associated with the
process of tissue repair.
Weeks oftreatment
FiG. 8.-Mucoprotein changes during radiotherapy. Initial values in brackets. 1 = Antral
carcinoma. 2. = Osteogenic sarcoma with extensive lung secondaries. 3.=Hodgkin's
disease. 4. = Large anaplastic careinomatous ulcer of neck. 5. = Carcinoma of floor of
mouth.
Data on the influence ofradiotherapy is limited to 5 cases, but it will be seen
from Fig. 9 that considerable changes were sometimes produced in both levels.
In the case ofurine all cases showed an initial fall, which was maintained for some
weeks in 4 ofthe 5 cases. The results with serum werelessregular, butit was noted
thatthe 2 cases showing thegreatest fall had the most marked therapeuticbenefit,
whilst the 2 cases showing a rise responded poorly to treatment.
DISCUSSION
The present study has confirmed previous reports as to the rise ofserum muco-
protein concentrations in cancer and has shown that a similar rise occurs in the
urine mucoprotein fraction which we have investigated. These changes, although
more striking for cancer, are not specific, as they also occur in infections and in the
collagen diseases. Their relation to cancer as a disease is largely unexplained,
although suggestions have been made that they are related to cellular proliferative
or degenerative processes (Greenspan, 1954). The sites of production of these
mucoproteins in cancer are at present unknown. It may seem surprising that as
much as 200 mg. ofthis mucoprotein are excreted daily by normal subjects in the
urine, which is usually considered to be protein-free, but it must be pointed out
that mucoproteins are of course not coagulable by heat and are not precipitated
by the usual protein precipitants.
The striking positive correlation between urine and serum mucoproteins which
we have found suggests that a part at least of the urinary fraction may be derived
from the blood. This conclusion is of interest in relation to recent work by Tamm
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and Horsfall (1950, 1952) and Porter and Tamm (1955) who have investigated a
urine mucoprotein which was homogeneous in the ultracentrifuge and electro-
phoretically at pH 86. They suggest that it may be derived from the mucous cells
of the bladder. This urine mucoprotein, which has not been detected in serum,
differsinseveralaspectsfromthefractionstudiedbyus. Thusourfraction, although
not homogeneous in the ultracentrifuge, has a main component with a inean
molecular weight of the order of 20,000 (Shooter, 1955, private communication)
in contrast to the molecular weight of 7 x 106 reported for the mucoprotein of
Tamm and Horsfall (Horsfall, 1954). Furthermore our fraction has a slower
electrophoretic mobility at pH 8*6. It is ofinterest to note that the electrophoretic
properties of our fraction, both at pH 8-6, where it migrates with the a-globulin,
and at pH 4-6, where two negatively charged components are observed (Anderson,
Lockey and Maclagan, 1955b) are very similar to the serum mucoprotein fraction
of Mehl, Golden and Winzler (1949). In addition the molecular weight (44,100) of
the major serum mucoprotein (Smith, Brown, Weimer and Winzler, 1950) is of
the same order as the mean molecular weight of our fraction. These facts support
the view that our urine mucoprotein fraction is, in fact, probably derived from the
blood by renal excretion.
Assuming that our urine mucoprotein fraction originates from the blood, it is
possible to calculate an approximate value for its renal clearance from the data
given in Table III. Normal subjects give a mean value of 99 ml. of serum cleared
of mucoprotein in 24 hours, and results in other groups vary from 77 for cancer to
137 for endocrine diseases. Although these are very low clearances they are
considerably higher than those of other serum proteins. Thus, from the data of
Rigas and Heller (1951) and others the renal clearance of serum albumin would
appear to be only 0*3 ml. per 24 hours. It appears therefore that the kidney
excretes the mucoprotein of the serum more readily than it does the other serum
proteins, presumably on account of smaller molecular size or different molecular
shape.
Mucoprotein levels have shown a definite relation to tumour site since eleva-
tions were particularly marked in cases of leukaemia, Hodgkin's disease and
lymphosarcoma-i.e. diseases where lymphatic glands are particularly affected.
Only very slight elevations were present in the case of tumours involving bone,
suich as plasmacytoma, osteogenic sarcoma and metastases confined to bones.
In addition there was the expected relationship with the extent of the malignant
process, patients with widely disseminated tumours tending to show the highest
values.
The effect of treatment on mucoprotein metabolism disclosed an interesting
difference between surgical and radiotherapeutic treatment. Operation for malig-
nant conditions nearly always produced a sharp rise in mucoprotein levels,
presumably due either to processes of tissue repair, or to the hormonal results of
stress (Kelly, Kirschvink and Ely, 1952). The rise was almost equally pronounced
after operations for non-malignant conditions. Our patients have not yet been
followed long enough to ascertain whether an eventual fall to within normal levels
would occur. Radiotherapy, on the other hand, while having a variable effect on
the serumlevels usually lowered the urine mucoprotein. There was some indication
that a fall in serum nmucoprotein concentration was related to a favourable clinical
response.
In general the correlation between the serum and urine mucoprotein levels
15§
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discussed above also applied to those individual cases that we have been able to
follow after surgical procedures and during therapeutic treatment. As regards
choice of test, either urine or serum mucoprotein estimations may be usefully
employed. Although we found the serum mucoprotein estimation somewhat less
reproducible than that of urine, the reasons for which we have discussed above, it
has the advantage of greater technical simplicity and of avoiding the need for a
24-hour urine collection.
While the disturbances of mucoprotein metabolism in cancer is of considerable
theoretical interest, mucoprotein estimations appear to be of little value as a
diagnostic aid in patients with suspected cancer, since high values are rarely found
in early or localised cases. It is possible that they may prove to be of value in
prognosis or in following the effects oftreatment, but more data would be required
to establish such a relationship.
SUMMARY
1. Urine and serum mucoprotein levels have been estimated in 114 cases of
cancer, in 215 cases of non-malignant disease, and in 63 normal subjects.
2. The serum values were expressed as mg. per 100 ml. and the urine values as
relative urine concentration (R.U.C.). These two values were closely correlated
with each other and it is suggested that the urinary mucoproteins originate in
part from the blood.
3. Both urine and serum levels were frequently above normal in cancer, but
similar elevations were also seen in inflammatory and in the collagen diseases.
Very high values occurred mainly in the cancer group.
4. In cancer the highest values were recorded in patients with widely dissemi-
nated disease, whether primary or secondary in nature. Results were particularly
striking in the lymphomata, while in malignant disease mainly confined to bone
very little elevation was found. Other cancers occupied an intermediate position.
5. The effect of surgical and radiotherapeutic treatment on the mucoprotein
levels was studied in a small series ofpatients. Operations almost always produced
a marked rise. The effect of radiotherapy was inconstant, but falling values
appeared to bear some relationship to a favourable tlherapeutic response.
We are much indebted to the Medical and Surgical Staff of Westminster
Hospital for permission to investigate their patients and to the Nursing Staff for
their willing and cheerful co-operation. The work has been made possible by
generous grants from the British Empire Cancer Campaign andfrom the Governor's
Discretionary Fund of Westminster Hospital.
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